You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
加科思-B(01167.HK)公布格萊雷塞治療結直腸癌臨床數據
阿思達克 06-29 16:33
加科思-B(01167.HK)公布,在第二屆JCA-AACR精準腫瘤醫學國際會上公布自主研發的KRAS G12C抑制劑格來雷塞(JAB-21822)單藥及與西妥昔單抗聯合用藥治療KRAS G12C突變晚期結直腸癌(CRC)的臨床數據。 在單藥治療研究中,客觀緩解率(ORR)為33.3%(11/33),疾病控制率(DCR)為90.9%(30/33)。中位無進展生存期(mPFS)為6.9個月。與西妥昔單抗聯合用藥的臨床試驗中,客觀緩解率為62.8%(27/43),疾病控制率為93%(40/43)。於2023年5月23日數據截止日期,中位無進展生存期數據尚未成熟。 從安全性來看,單藥和聯合用藥的治療相關性不良事件(TRAE)主要為1-2級。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account